Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy
Authors
Keywords
Overall Survival, Hypothyroidism, Sorafenib, Sunitinib, Gefitinib
Journal
DRUG SAFETY
Volume 36, Issue 6, Pages 413-426
Publisher
Springer Nature
Online
2013-05-02
DOI
10.1007/s40264-013-0050-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval)
- (2013) Rashmi R. Shah et al. DRUG SAFETY
- Skin Rash could Predict the Response to EGFR Tyrosine Kinase Inhibitor and the Prognosis for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
- (2013) Hong-bing Liu et al. PLoS One
- Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib‡
- (2012) S. George et al. ANNALS OF ONCOLOGY
- Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer
- (2012) Tomohiro Suzumura et al. BMC CANCER
- Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials
- (2012) Wei-Xiang Qi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Thyroid Dysfunction in Patients Treated With Sunitinib or Sorafenib
- (2012) Julia Clemons et al. Clinical Genitourinary Cancer
- Thyroid Dysfunction in Patients Treated with Tyrosine Kinase Inhibitors, Sunitinib, Sorafenib and Axitinib, for Metastatic Renal Cell Carcinoma
- (2012) M. Daimon et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Risk of Rash in Cancer Patients Treated with Vandetanib: Systematic Review and Meta-Analysis
- (2012) Alyx C. Rosen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Maximum-Tolerated Dose, Optimum Biologic Dose, or Optimum Clinical Value: Dosing Determination of Cancer Therapies
- (2012) John L. Marshall JOURNAL OF CLINICAL ONCOLOGY
- Intrapatient Cetuximab Dose Escalation in Metastatic Colorectal Cancer According to the Grade of Early Skin Reactions: The Randomized EVEREST Study
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: A literature-based meta-analysis of 24 trials
- (2012) Fausto Petrelli et al. LUNG CANCER
- The Association of Rash Severity With Overall Survival
- (2012) Edward J. Stepanski et al. PANCREAS
- Advances in the Management of Cutaneous Toxicities of Targeted Therapies
- (2012) Caroline Robert et al. SEMINARS IN ONCOLOGY
- The Double Edged Sword of Bleeding and Clotting from VEGF Inhibition in Renal Cancer Patients
- (2012) Guru Sonpavde et al. Current Oncology Reports
- Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer
- (2011) A C Mita et al. BRITISH JOURNAL OF CANCER
- Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib
- (2011) Jenny J. Kim et al. CANCER
- Effects of Novel Angiogenesis Inhibitors for the Treatment of Cancer on the Cardiovascular System
- (2011) Babak Nazer et al. CIRCULATION
- The Phosphatase Inhibitor Menadione (Vitamin K3) Protects Cells from EGFR Inhibition by Erlotinib and Cetuximab
- (2011) R. Perez-Soler et al. CLINICAL CANCER RESEARCH
- Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors
- (2011) B. I. Rini et al. CLINICAL CANCER RESEARCH
- Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors
- (2011) F. A. L. M. Eskens et al. CLINICAL CANCER RESEARCH
- Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts
- (2011) Jennifer Nam Choi CLINICS IN DERMATOLOGY
- Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer
- (2011) V. Hirsh Current Oncology
- Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: Comparison with thyroid function
- (2011) Kazuhiro Kitajima et al. EUROPEAN JOURNAL OF RADIOLOGY
- Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients
- (2011) Yutaka Fujiwara et al. INVESTIGATIONAL NEW DRUGS
- Vascular Endothelial Growth Factor Receptor 2 Direct Interaction with Nephrin Links VEGF-A Signals to Actin in Kidney Podocytes
- (2011) Claudia Bertuccio et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Sunitinib-Induced Hypothyroidism Is due to Induction of Type 3 Deiodinase Activity and Thyroidal Capillary Regression
- (2011) Mariëtte H. W. Kappers et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Oncogenic Targets, Magnitude of Benefit, and Market Pricing of Antineoplastic Drugs
- (2011) Eitan Amir et al. JOURNAL OF CLINICAL ONCOLOGY
- Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
- (2011) B. I. Rini et al. JNCI-Journal of the National Cancer Institute
- Noncardiac Vascular Toxicities of Vascular Endothelial Growth Factor Inhibitors in Advanced Cancer: A Review
- (2011) D. Keefe et al. ONCOLOGIST
- Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion
- (2010) K. Potthoff et al. ANNALS OF ONCOLOGY
- Angiogenesis Inhibitors: Current Strategies and Future Prospects
- (2010) K. M. Cook et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Hypothyroidism in patients with renal cell carcinoma
- (2010) Manuela Schmidinger et al. CANCER
- Rapid Development of Hypertension and Proteinuria with Cediranib, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor
- (2010) E. S. Robinson et al. Clinical Journal of the American Society of Nephrology
- Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma
- (2010) Shuichi Sato et al. ENDOCRINE JOURNAL
- Sorafenib-Induced Hypothyroidism Is Associated with Increased Type 3 Deiodination
- (2010) Randa M. Abdulrahman et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Isotretinoin Plus Clindamycin Seem Highly Effective Against Severe Erlotinib-Induced Skin Rash in Advanced Non-small Cell Lung Cancer
- (2010) Paolo Bidoli et al. Journal of Thoracic Oncology
- Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib
- (2010) B. Vincenzi et al. ONCOLOGIST
- Cardiovascular Safety of VEGF-Targeting Therapies: Current Evidence and Handling Strategies
- (2010) F. Girardi et al. ONCOLOGIST
- Treatment of Epidermal Growth Factor Receptor Antagonist-Induced Skin Rash: Results of a Survey among German Oncologists
- (2010) Jessica C. Hassel et al. ONKOLOGIE
- Biology of Anti-Angiogenic Therapy–Induced Thrombotic Microangiopathy
- (2010) Vera Eremina et al. SEMINARS IN NEPHROLOGY
- Sunitinib Induces Hypothyroidism with a Markedly Reduced Vascularity
- (2010) Noriko Makita et al. THYROID
- Sunitinib-Induced Thyrotoxicosis Followed by Persistent Hypothyroidism with Shrinkage of Thyroid Volume
- (2010) Kanako Sakurai et al. TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
- Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib
- (2010) L. M. Riesenbeck et al. WORLD JOURNAL OF UROLOGY
- Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
- (2009) Kristy J. Gotink et al. ANGIOGENESIS
- Management of hypertension in angiogenesis inhibitor-treated patients
- (2009) H. Izzedine et al. ANNALS OF ONCOLOGY
- Thrombosis associated with angiogenesis inhibitors
- (2009) Francesca Elice et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: A phase I study in Japanese patients
- (2009) Toru Mukohara et al. CANCER SCIENCE
- Mutations and Response to Epidermal Growth Factor Receptor Inhibitors
- (2009) P. Laurent-Puig et al. CLINICAL CANCER RESEARCH
- Gastrointestinal toxicities of novel agents in cancer therapy
- (2009) Amani Asnacios et al. EUROPEAN JOURNAL OF CANCER
- VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management
- (2009) Hassane Izzedine et al. EUROPEAN JOURNAL OF CANCER
- Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions
- (2009) Hester van Cruijsen Frontiers in Bioscience-Landmark
- Effect of the Multitargeted Receptor Tyrosine Kinase Inhibitor, ABT-869 [N-(4-(3-Amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea], on Blood Pressure in Conscious Rats and Mice: Reversal with Antihypertensive Agents and Effect on Tumor Growth Inhibition
- (2009) P. H. Franklin et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy
- (2009) Francesco Torino et al. Nature Reviews Clinical Oncology
- Analysis of dermatologic events in patients with cancer treated with lapatinib
- (2008) M. E. Lacouture et al. BREAST CANCER RESEARCH AND TREATMENT
- The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation
- (2008) P Wolter et al. BRITISH JOURNAL OF CANCER
- Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics
- (2008) Ming Hui Chen et al. CIRCULATION
- Hypertension and Rarefaction during Treatment with Telatinib, a Small Molecule Angiogenesis Inhibitor
- (2008) N. Steeghs et al. CLINICAL CANCER RESEARCH
- Documentation of Thyroid Function in Clinical Studies With Sunitinib: Why Does It Matter?
- (2008) David H. Garfield et al. JOURNAL OF CLINICAL ONCOLOGY
- KRASMutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
- (2008) Astrid Lièvre et al. JOURNAL OF CLINICAL ONCOLOGY
- VEGF Inhibition and Renal Thrombotic Microangiopathy
- (2008) Vera Eremina et al. NEW ENGLAND JOURNAL OF MEDICINE
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now